Full-Time

Associate Director

Clinical Pharmacology

Posted on 8/19/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$175k - $210kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
R
Requirements
  • Ph.D. or Pharm.D. with 5+ years of relevant industry experience in Clinical and Quantitative pharmacology.
  • Expertise in clinical pharmacology, hands-on modeling, and simulation skills using NONMEM, R, and/or other modeling and simulation software. Experience with population PK, exposure-response, and advanced mechanistic PK/PD models.
  • Track record of applying modeling and simulation methodologies to inform and accelerate drug development.
  • Well-informed in current and emerging scientific standards of regulatory requirements and expectations.
  • Excellent verbal and written communication skills, and ability to clearly convey complex concepts and findings to both non-specialist and specialist audiences.
  • Strong interpersonal skills, and ability to influence development project and management teams.
  • A critical thinker and passionate team player with high energy who thrives in a dynamic and fast-paced environment.
Responsibilities
  • Responsible for clinical pipeline delivery through major milestones including IND/CTA, EOP2, and marketing applications NDA/sNDA.
  • Lead the design and execution of an integrated clinical pharmacology and modeling and simulation strategy to guide the clinical development plan.
  • Apply state-of-the-art quantitative pharmacology analyses, including PBPK, translational PK/PD, population PK, exposure-response analyses, and system pharmacology, to guide dose/schedule selection and recommended phase 2 dose and schedule (RP2Ds) selection.
  • Author and provide technical input for regulatory documents and submissions related to all aspects of clinical pharmacology (including protocol, IB, briefing package, etc) and responses to regulatory questions.
  • Engage and work with consultants and/or CROs on clinical pharmacology activities to complement in-house knowledge/expertise and capacities.
  • Represent the clinical pharmacology function in project teams and build strong working relationships with cross-functional teams to impact critical decisions.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • Strong investor confidence shown by recent upsized public offering.
  • Growing interest in targeted therapies aligns with their RAS-focused treatments.

What critics are saying

  • EQRx acquisition may lead to integration challenges and cultural clashes.
  • $600M public stock offering could result in shareholder dilution.
  • Focus on RAS-driven cancers limits market scope and growth potential.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE